This photo provided by the Center for Psychedelic Therapy Research shows a Yehuda Lab MDMA-assisted therapy treatment room at the James J. Peters Department of Veterans Affairs Medical Center in the Bronx borough of New York. On Friday, May 31, 2024, the Food and Drug Administration posted its initial review of MDMA, the mind-altering club drug, as a treatment for PTSD. In their assessment, FDA scientists said that patients who received MDMA and talk therapy showed “rapid, clinically meaningful, durable improvements in their PTSD symptoms,." But they also called the research “challenging to interpret,” and questioned how long the benefits might last. (OH Prema, Center for Psychedelic Therapy Research via AP)